(0.22%) 5 143.00 points
(0.21%) 38 522 points
(0.32%) 17 902 points
(-0.54%) $83.40
(2.03%) $1.962
(0.03%) $2 348.00
(0.30%) $27.62
(0.84%) $929.85
(-0.19%) $0.933
(-0.32%) $10.99
(-0.27%) $0.798
(1.15%) $92.93
Live Chart Being Loaded With Signals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases...
Stats | |
---|---|
本日の出来高 | 4 913.00 |
平均出来高 | 60 840.00 |
時価総額 | 220.91B |
EPS | €0.881 ( 2023-09-30 ) |
Last Dividend | €0.718 ( 2023-08-10 ) |
Next Dividend | €0 ( N/A ) |
P/E | 37.80 |
ATR14 | €0.134 (0.09%) |
ボリューム 相関
AstraZeneca PLC 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
AstraZeneca PLC 相関 - 通貨/商品
AstraZeneca PLC 財務諸表
Annual | 2023 |
収益: | €45.81B |
総利益: | €37.54B (81.95 %) |
EPS: | €3.84 |
FY | 2023 |
収益: | €45.81B |
総利益: | €37.54B (81.95 %) |
EPS: | €3.84 |
FY | 2022 |
収益: | €44.35B |
総利益: | €31.96B (72.06 %) |
EPS: | €2.12 |
FY | 2021 |
収益: | €37.42B |
総利益: | €24.98B (66.76 %) |
EPS: | €0.0800 |
Financial Reports:
No articles found.
AstraZeneca PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.764 (N/A) |
€0 (N/A) |
€1.628 (N/A) |
€0 (N/A) |
€0.718 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.540 | 2004-02-18 |
Last Dividend | €0.718 | 2023-08-10 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | €40.56 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.05 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.82 | |
Div. Directional Score | 8.83 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TTK.DE | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
DWD.DE | Ex Dividend Junior | 2023-07-28 | Quarterly | 0 | 0.00% | |
MZX.DE | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
8TRA.DE | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
XGR2.DE | Ex Dividend Junior | 2023-06-08 | Annually | 0 | 0.00% | |
FPMB.DE | Ex Dividend King | 2023-10-12 | Quarterly | 0 | 0.00% | |
PFE.DE | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
ASME.DE | Ex Dividend Knight | 2023-08-01 | Semi-Annually | 0 | 0.00% | |
HNR1.DE | Ex Dividend Junior | 2023-05-04 | Annually | 0 | 0.00% | |
SDF.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.133 | 1.500 | 7.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0619 | 1.200 | 7.94 | 9.52 | [0 - 0.3] |
returnOnEquityTTM | 0.168 | 1.500 | 9.25 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.706 | -1.000 | 2.94 | -2.94 | [0 - 1] |
currentRatioTTM | 0.886 | 0.800 | -0.572 | -0.458 | [1 - 3] |
quickRatioTTM | 0.278 | 0.800 | -3.07 | -2.46 | [0.8 - 2.5] |
cashRatioTTM | 0.271 | 1.500 | 9.60 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.338 | -1.500 | 4.37 | -6.56 | [0 - 0.6] |
interestCoverageTTM | 5.33 | 1.000 | 9.14 | 9.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.26 | 2.00 | 7.91 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.73 | 2.00 | 8.13 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.923 | -1.500 | 6.31 | -9.46 | [0 - 2.5] |
grossProfitMarginTTM | 0.820 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.184 | 1.000 | 8.32 | 8.32 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.281 | 1.000 | 9.55 | 9.55 | [0.2 - 2] |
assetTurnoverTTM | 0.465 | 0.800 | -0.230 | -0.184 | [0.5 - 2] |
Total Score | 10.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 36.82 | 1.000 | 6.38 | 0 | [1 - 100] |
returnOnEquityTTM | 0.168 | 2.50 | 9.52 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.73 | 2.00 | 8.76 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.514 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.26 | 2.00 | 7.91 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.706 | 1.500 | 2.94 | -2.94 | [0 - 1] |
pegRatioTTM | 2.79 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.204 | 1.000 | 7.41 | 0 | [0.1 - 0.5] |
Total Score | 6.82 |
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。